Local News

• Wyeth names Michael Kamarck President, Technical Operations & Product Supply  Wyeth announced that Michael Kamarck, Ph.D., 57, has been promoted to President, Technical Operations & Product Supply (TO&PS). Dr. Kamarck will be responsible for all aspects of technical operations and product supply for Wyeth.
  Wyeth November 20, 2008  
• Wyeth declares preferred stock dividend  At a meeting of the Board of Directors of Wyeth, a dividend of fifty cents ($0.50) per share on the outstanding shares of Preferred Stock was declared payable on January 2, 2009 to stockholders of record at the close of business on December 12, 2008.
  Wyeth November 20, 2008  
• Tibotec begins enrollment in Europe for Phase III trial of telaprevir  Tibotec BVBA announced that it has begun enrolling patients in its phase III study of telaprevir (VX-950), an investigational protease inhibitor (PI), in patients with chronic genotype 1 hepatitis C virus (HCV) for whom the current standard treatment has not been successful.
  Johnson & Johnson November 20, 2008  
• Tibotec presents interim findings for TMC435, an investigational genotype 1 HepC treatment  New clinical data show antiviral activity of TMC435, an investigational protease inhibitor (PI) being developed by Tibotec BVBA for the treatment of chronic hepatitis C virus (HCV) infection.
  Johnson & Johnson November 20, 2008  
• AstraZeneca to divest Nordic over-the-counter portfolio  AstraZeneca announced the divestment to GlaxoSmithKline of a portfolio of over-the-counter (OTC) products predominantly sold in Sweden. The decision reinforces AstraZeneca's strategy to focus on innovation in prescription medicines.
  AstraZeneca November 20, 2008  
• Ortho Biotech announces NDA submission for trabectedin  Ortho Biotech Products announced the submission of a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for trabectedin when administered in combination with DOXIL(R) (doxorubicin HCI liposome injection) for the treatment of women with relapsed ovarian cancer (ROC).
  Johnson & Johnson November 20, 2008  
• Chembio ships first DPP(R) tests  Chembio Diagnostics has completed the first shipment of products based upon its patented Dual Path Platform or DPP(R) product technology. This shipment represents a significant milestone for the Company's strategy to develop OEM and branded products utilizing its Dual Path Platform technology.
  Chembio Diagnostics, Inc. November 20, 2008  
• FDA accepts Vanda Pharmaceuticals iloperidone resubmission and sets new action date  Vanda Pharmaceuticals reported that the FDA has accepted Vanda's resubmission of the iloperidone New Drug Application (NDA). Vanda's resubmission was a Complete Response to the not approvable action letter that the company received on July 25, 2008.
  Vanda Pharmaceuticals Inc. November 20, 2008  
• ImClone Systems' state-of-the-art manufacturing facility receives FDA approval  ImClone Systems announced that it has received approval from the Food and Drug Administration for its state-of-the-art "BB50" manufacturing facility to manufacture multiple products.
  ImClone System Incorporated November 20, 2008  
• Pfizer withdraws application to switch Viagra to non-prescription status in Europe  Pfizer announced that it has withdrawn its application to switch the legal status of the 50 mg tablet strength of Viagra from 'prescription only' to 'non-prescription' in the European Union (EU).
  Pfizer Inc. November 20, 2008  

   (next 10 articles)